Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.adaj.2019.07.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Celecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis.
BMB Rep
January 2025
Division of Rheumatology, Regional Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon 35015, Korea.
Spondyloarthritis (SpA) is a chronic inflammatory disease that leads to ankylosis of the axial skeleton. Celecoxib (cyclooxygenase-2 inhibitor, COX-2i) inhibited radiographic progression in a clinical study of SpA, but in the following study, diclofenac (COX-2 non-selective) failed to show that inhibition. Our study aimed to investigate whether nonsteroidal anti-inflammatory drugs (NSAIDs) inhibited bone progression in SpA, and whether celecoxib had a unique function (independent of the COX-inhibitor), compared with the other NSAIDs.
View Article and Find Full Text PDFDrug molecules beyond chemical biology: fluorescence- and DFT-based investigations for fluoride ion sensing and the trace detection of chloroform.
RSC Adv
November 2024
State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences Changchun 130022 P. R. China.
Article Synopsis
- Excessive fluoride use and chloroform exposure pose health risks, prompting the need for effective sensors to monitor these substances.
- Researchers investigated etoricoxib (ECX) as a safe and available sensor, revealing its strong fluorescence response for detecting fluoride and chloroform at very low levels.
- Advanced analyses, including UV-Vis and DFT studies, confirmed that ECX operates through non-covalent interactions, making it a promising tool for real-time detection of fluoride and moisture in various samples.
Potential Effect of Etoricoxib in Reducing Inflammation in Methotrexate-Induced Pulmonary Injury in Rats: Role of Oxidative Stress and the TLR4/p38-MAPK/NF-κB Signaling Pathway.
Inflammation
November 2024
Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Article Synopsis
- Chemotherapy drugs like Methotrexate (MTX) can cause serious lung damage, with MTX being particularly toxic and having various side effects, including lung injury.
- The study investigated the effect of etoricoxib (ETO) in reducing MTX-induced lung damage in male rats, with different treatment groups comparing controls, MTX alone, ETO alone, and ETO after MTX.
- Results showed that ETO improved lung tissue structure and restored balance in oxidant/antioxidant levels, while also normalizing inflammatory markers and pathways linked to lung inflammation, suggesting ETO may protect against MTX toxicity.
Nephro- and Cardiotoxic Effects of Etoricoxib: Insights into Arachidonic Acid Metabolism and Beta-Adrenergic Receptor Expression in Experimental Mice.
Pharmaceuticals (Basel)
October 2024
Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Etoricoxib is a widely used anti-inflammatory drug, but its safety profile concerning cardiovascular and renal health remains inadequately explored. This study aimed to assess the nephro- and cardiotoxic effects of etoricoxib in a murine model, with a focus on its impact on arachidonic acid-metabolizing enzymes and beta-adrenergic receptors associated with drug-induced toxicity. Thirty-five mice were randomly assigned to five groups: control, low-dose etoricoxib, high-dose etoricoxib, low-dose celecoxib, and high-dose celecoxib (a well-known nephro- and cardiotoxic NSAID).
View Article and Find Full Text PDFLeveraging solid solubility and miscibility of etoricoxib in Soluplus® towards manufacturing of 3D printed etoricoxib tablets by additive manufacturing.
Int J Pharm
December 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, West Bengal 700054, India. Electronic address:
This research focuses on exploring the solid solubility and miscibility of Etoricoxib, a poorly water-soluble anti-inflammatory drug, within Soluplus®, a polymer used as a matrix for 3D-printed tablets. By utilizing hot-melt extrusion (HME), the drug was dispersed within Soluplus® to enhance its solubility. The extrudates were then employed in 3D printing to create customized solid oral dosage form.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!